{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Colle de fibrine : Questions médicales les plus fréquentes",
"headline": "Colle de fibrine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Colle de fibrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-07",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Colle de fibrine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Fibrine",
"url": "https://questionsmedicales.fr/mesh/D005337",
"about": {
"@type": "MedicalCondition",
"name": "Fibrine",
"code": {
"@type": "MedicalCode",
"code": "D005337",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.270"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Colle de fibrine",
"alternateName": "Fibrin Tissue Adhesive",
"code": {
"@type": "MedicalCode",
"code": "D015718",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sarah J Wu",
"url": "https://questionsmedicales.fr/author/Sarah%20J%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA."
}
},
{
"@type": "Person",
"name": "Xuanhe Zhao",
"url": "https://questionsmedicales.fr/author/Xuanhe%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA."
}
},
{
"@type": "Person",
"name": "Qian Li",
"url": "https://questionsmedicales.fr/author/Qian%20Li",
"affiliation": {
"@type": "Organization",
"name": "National Center for International Research of Micro-Nano Molding Technology, 12636Zhengzhou University, Zhengzhou, China."
}
},
{
"@type": "Person",
"name": "Yang Li",
"url": "https://questionsmedicales.fr/author/Yang%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China."
}
},
{
"@type": "Person",
"name": "Fernando Campos",
"url": "https://questionsmedicales.fr/author/Fernando%20Campos",
"affiliation": {
"@type": "Organization",
"name": "Department of Histology and Tissue Engineering Group, Faculty of Medicine, University of Granada, Granada, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy of topical tranexamic acid to reduce bleeding in endoscopic sinus surgery for chronic rhinosinusitis with polyposis.",
"datePublished": "2022-07-28",
"url": "https://questionsmedicales.fr/article/35900386",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00405-022-07563-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical 5-aminolevulinic acid photodynamic therapy for cervical high-grade squamous intraepithelial lesions.",
"datePublished": "2022-07-26",
"url": "https://questionsmedicales.fr/article/35905829",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pdpdt.2022.103037"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tamoxifen Citrate Containing Topical Nanoemulgel Prepared by Ultrasonication Technique: Formulation Design and In Vitro Evaluation.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35877541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/gels8070456"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of Topical ρ-Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35848984",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/OPX.0000000000001925"
}
},
{
"@type": "ScholarlyArticle",
"name": "Design and development of essential oil based nanoemulsion for topical application of triclosan for effective skin antisepsis.",
"datePublished": "2022-06-28",
"url": "https://questionsmedicales.fr/article/35666086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10837450.2022.2087085"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Fibrine",
"item": "https://questionsmedicales.fr/mesh/D005337"
},
{
"@type": "ListItem",
"position": 6,
"name": "Colle de fibrine",
"item": "https://questionsmedicales.fr/mesh/D015718"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Colle de fibrine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Colle de fibrine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Colle de fibrine",
"description": "Comment évaluer l'efficacité de la colle de fibrine ?\nQuels tests sont utilisés avant l'application ?\nY a-t-il des contre-indications à son utilisation ?\nComment détecter une réaction allergique ?\nQuels signes indiquent une mauvaise cicatrisation ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Colle de fibrine",
"description": "Quels symptômes peuvent apparaître après l'application ?\nComment reconnaître une infection post-opératoire ?\nY a-t-il des effets secondaires fréquents ?\nQuels signes d'allergie doivent alerter ?\nPeut-on avoir des douleurs persistantes ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Colle de fibrine",
"description": "Comment prévenir les infections après application ?\nQuelles précautions prendre avant l'application ?\nComment éviter les réactions allergiques ?\nY a-t-il des recommandations pour les patients ?\nQuels facteurs de risque doivent être surveillés ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Colle de fibrine",
"description": "Comment la colle de fibrine est-elle appliquée ?\nQuels types de blessures peuvent être traités ?\nLa colle de fibrine remplace-t-elle les sutures ?\nQuels soins sont nécessaires après application ?\nPeut-on utiliser la colle de fibrine en cas d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Colle de fibrine",
"description": "Quelles complications peuvent survenir ?\nComment gérer une réaction allergique ?\nQuels signes d'infection nécessitent une attention médicale ?\nPeut-on avoir des cicatrices après utilisation ?\nQuelles sont les conséquences d'une mauvaise application ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Colle de fibrine",
"description": "Quels sont les principaux facteurs de risque ?\nLes personnes âgées sont-elles plus à risque ?\nLes maladies chroniques influencent-elles le risque ?\nComment le tabagisme affecte-t-il le risque ?\nLes antécédents chirurgicaux augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D015718?mesh_terms=Multicenter+Studies+as+Topic&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité de la colle de fibrine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'observation de la cicatrisation et la réduction des hémorragies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés avant l'application ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de coagulation sanguine peuvent être réalisés pour évaluer la compatibilité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des contre-indications à son utilisation ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les allergies aux composants de la colle ou des troubles de la coagulation sont des contre-indications."
}
},
{
"@type": "Question",
"name": "Comment détecter une réaction allergique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique peut se manifester par des rougeurs, démangeaisons ou gonflements au site d'application."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une mauvaise cicatrisation ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une inflammation persistante, une déhiscence ou une infection peuvent indiquer une mauvaise cicatrisation."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent apparaître après l'application ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des rougeurs, gonflements ou douleurs au site d'application peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection post-opératoire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une infection peut se manifester par une chaleur, une douleur accrue, ou un écoulement purulent."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires fréquents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des démangeaisons ou des réactions au site d'application."
}
},
{
"@type": "Question",
"name": "Quels signes d'allergie doivent alerter ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des démangeaisons ou un œdème peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des douleurs persistantes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs persistantes peuvent survenir, nécessitant une évaluation médicale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections après application ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène et suivre les instructions post-opératoires aide à prévenir les infections."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avant l'application ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les allergies et les antécédents médicaux est essentiel avant l'application."
}
},
{
"@type": "Question",
"name": "Comment éviter les réactions allergiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test cutané préalable peut aider à identifier les allergies potentielles aux composants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les patients ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients doivent suivre les conseils médicaux et signaler tout symptôme inhabituel."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque doivent être surveillés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents d'allergies et les troubles de la coagulation sont des facteurs de risque importants."
}
},
{
"@type": "Question",
"name": "Comment la colle de fibrine est-elle appliquée ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement appliquée par pulvérisation ou en gouttes sur les tissus à unir."
}
},
{
"@type": "Question",
"name": "Quels types de blessures peuvent être traités ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour des coupures, des incisions chirurgicales ou des lésions cutanées."
}
},
{
"@type": "Question",
"name": "La colle de fibrine remplace-t-elle les sutures ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut remplacer les sutures dans certains cas, mais n'est pas toujours appropriée."
}
},
{
"@type": "Question",
"name": "Quels soins sont nécessaires après application ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est important de garder la zone propre et sèche, et de surveiller les signes d'infection."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser la colle de fibrine en cas d'infection ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, son utilisation est contre-indiquée en présence d'une infection active."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections, des réactions allergiques ou une mauvaise cicatrisation peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de réaction allergique, il est crucial de consulter un médecin immédiatement."
}
},
{
"@type": "Question",
"name": "Quels signes d'infection nécessitent une attention médicale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des rougeurs, chaleur, douleur accrue ou écoulement purulent nécessitent une attention médicale."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des cicatrices après utilisation ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des cicatrices peuvent se former, surtout si la cicatrisation est compromise."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une mauvaise application ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise application peut entraîner des déhiscences, infections ou cicatrisation inadéquate."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les allergies, les troubles de la coagulation et les infections antérieures sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru de complications lors de l'utilisation."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète peuvent augmenter le risque d'infection et de mauvaise cicatrisation."
}
},
{
"@type": "Question",
"name": "Comment le tabagisme affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme peut retarder la cicatrisation et augmenter le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les antécédents chirurgicaux augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de complications chirurgicales peuvent augmenter le risque lors de nouvelles interventions."
}
}
]
}
]
}
To evaluate the efficacy of topical tranexamic acid (TXA) in reducing intraoperative and immediate postoperative bleeding during functional endoscopic sinus surgery (FESS) among patients with chronic ...
This is a double-blind randomized clinical trial, involving 26 patients with CRSwNP, who underwent FESS for failed medical therapy. The intervention nostril was packed with ribbon gauze soaked in 500 ...
There was no significant difference in intraoperative bleeding between the intervention (1.54 ± 0.71) and control nostrils (1.69 ± 0.55) with p = 0.172. The amount of bleeding in the postoperative per...
We found that the nasal packing soaked in TXA reduced intraoperative and immediate postoperative bleeding. It is a safe, efficacious and cost-effective alternative to Moffett's solution during FESS an...
FF-2015-232, 2015....
To evaluate the efficacy of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of high-grade squamous intraepithelial lesions of the cervix (HSIL)....
This retrospective study included 22 female patients with histologically confirmed HSIL and high-risk human papillomavirus (HR-HPV) infections. Patients were treated with ALA-PDT once a week for a tot...
Three months after 5-ALA PDT, the histologic disappearance rate was 81.82% (18/22), while the HPV clearance rate was 54.55% (12/22). At the 6 months checkpoint, the HSIL disappearance rate was 90.91% ...
Topical 5-ALA PDT is an effective treatment for cervical HSIL with HR-HPV infection....
The present study aims to design and develop a nanoemulgel formulation of Tamoxifen citrate (TAM), a water-insoluble, potent anticancer drug, using the spontaneous emulsification method to improve top...
The real-world pharmacological use of netarsudil shows that it can produce a clinically significant decrease in intraocular pressure for a small group of patients, even if they are already taking thre...
This study aimed to assess the effectiveness of netarsudil in reducing intraocular pressure among veterans with advanced glaucoma on maximally tolerated medical therapy....
All patients with glaucoma who received netarsudil between June 2018 and April 2020 from the West Los Angeles Veterans Administration Medical Center were reviewed. Inclusion criteria included a minimu...
Of 200 patients prescribed netarsudil, 42 patients (eyes) met the enrollment criteria. The mean age of these patients was 75.7 years (95% confidence interval [CI], 73.0 to 78.4 years), 64% were of Afr...
Netarsudil may produce a clinically significant intraocular pressure reduction in up to a third of the patients with advanced glaucoma already on maximally tolerated medical therapy....
The skin acts as a physical barrier to protect the body from the external physical and chemical environment. When skin is infected, the outer epidermal barrier is compromised and colonized with microb...
Xanthoma pathogenesis is speculated to be associated with oxidized low-density lipoprotein (ox-LDL) deposition, although this remains unclear. Most patients with diffuse plane xanthomas present elevat...
Single-center studies or randomized controlled trials have evaluated the impact of radiotherapy for bone metastases on quality of life (QOL). We investigated the real-world impact of radiotherapy for ...
We conducted a prospective observational study at 26 centers in Japan. Of 333 patients who received radiotherapy for bone metastases between December 2020 and March 2021, 232 (70%) were enrolled in th...
QOL scores showed significant improvement at two-month follow-up in seven (global health status/QOL, emotional functioning, pain, insomnia, painful sites, pain characteristics and functional interfere...
Radiotherapy for bone metastases performed in daily practice is effective in improving some scales of QOL....
We used Cluster Analysis of Migraine-associated Symptoms (CAMS) to critically evaluate current International Classification of Headache Disorders-Third Edition (ICHD-3) migraine-associated symptoms cr...
Diagnostic criteria play a central role in guiding clinical trial inclusion, and therefore available treatments. Migraine and tension-type headaches (TTH) are differentiated in ICHD-3 by many headache...
In this multisite retrospective cross-sectional study, we evaluated ICHD-3 migraine criteria. Youth aged 6-17 years with migraine (including probable migraine) or TTH were included in the analysis. We...
Of the 9017 participants included in this study, 66.7% were female and had a median (interquartile range) age of 13 (10-15) years. Most participants had migraine or probable migraine (99.0%), and the ...
The ICHD-3 captures the most prevalent migraine-associated symptoms; however, many youths with probable migraine who do not meet full criteria due to insufficient associated symptoms nonetheless exper...
The misuse or abuse and dependence of medications containing codeine continue to be a major global public health concern. This study aimed to investigate the role of community pharmacists in preventin...
A cross-sectional study involving 226 community pharmacists from various community pharmacies across multiple cities of Saudi Arabia was conducted from 09 May 2023 to 09 October 2023. Study data were ...
The primary indicators that community pharmacists considered when suspecting cases of abuse or misuse and dependence included customers who requested a larger quantity of the medication (88.5%), frequ...
Community pharmacists, being frequently the initial point of contact easily reachable, possess the capability to greatly assist in identifying the patients and averting abuse or misuse and dependence ...
In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N) with and without ipilimumab (N+I) and pro...
Patients were randomized (non-comparative) to receive either N or N+I. The primary endpoint was a 6-month confirmed response rate (CRR) defined by Response Evaluation Criteria in Solid Tumors version ...
A total of 66 patients were evaluated for the primary endpoint with disease including gastrointestinal stromal tumor (GIST, n=18), undifferentiated pleomorphic sarcoma (UPS, n=24), and dedifferentiate...
This expansion cohort reaffirms the outcomes of A091401. There remains a pressing need to determine the role of and predictive biomarkers for immunotherapy in sarcoma....
NCT02500797....